Financing ·
Disc Medicine prices $450M equity offering of 6 million shares at $75 each
IRONDisc Medicine, Inc.
Disc Medicine priced an upsized underwritten public offering of 6,000,000 shares of common stock at $75.00 per share, generating gross proceeds of approximately $450 million before deducting underwriting discounts and commissions. The company granted the underwriters a 30-day option to purchase up to an additional 900,000 shares. Net proceeds are expected to be approximately $422.4 million, or roughly $485.9 million if the over-allotment is exercised in full. The offering closed on October 22, 2026, and funds will support clinical development of product candidates like bitopertin for hematologic diseases as well as working capital needs.